Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
The wrestling hall of fame star 'Rowdy' Roddy Piper has died aged 61.
Labour has called for compensation from the French government to be paid to Britons affected by the chaos at Calais.
Andy Burnham warns far-left supporters of fellow Labour leadership candidate Jeremy Corbyn are putting party at risk of a 1980s-style split.